Preclinical data show HT-4253 reduces neuroinflammation and tau pathology; a second details a Phase 2a biomarker trial in pre-symptomatic APOE4 carriers via UAE genomics.
Alzheimer’s disease is one of the world’s most pressing health challenges, affecting more than 55 million people globally; a number expected to nearly triple by 2050.
The designation follows encouraging Phase 2 clinical trial results.
New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement.
Halia Therapeutics Expands to Abu Dhabi
Halia Therapeutics Named as 2025 Top 10 Longevity Breakthrough Award Winner
Halia Therapeutics Published in Journey of Drug Targeting
Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer’s and other neurodegenerative diseases.
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
Trial underscores IROS’s commitment to developing innovative therapies for unmet medical needs
Novel targets for managing inflammation hold the promise of greater efficacy and safety for diseases not widely viewed as inflammatory in nature.
Halia Therapeutics’ CEO, David Bearss, recently discussed the FDA’s Project Optimus in The Wall Street Journal.